PD-L1 levels, TP53 mutation profiles, and survival outcomes in pancreatic cancer differ by immune-nutritional status
The findings suggest poorer outcome, higher PD-L1 expression and distinct p53 mutation status of patients with SPS<sup>+</sup>. These patterns may contribute to PDAC management and strategic deployment of immunotherapy and targeted therapy.
Authors
- Zefeng Li (ORCID: https://orcid.org/0000-0003-4405-8872)
- Chongyuan Sun
- Su-sheng Shi (ORCID: https://orcid.org/0000-0003-0580-4844)
- Dongbing Zhao (ORCID: https://orcid.org/0000-0003-2583-1575)
- Hu Ren (ORCID: https://orcid.org/0000-0001-7274-287X)
- Penghui Niu (ORCID: https://orcid.org/0000-0002-0668-6950)
- Fei He (ORCID: https://orcid.org/0000-0002-4828-7624)
- Zheng Li (ORCID: https://orcid.org/0000-0002-6141-4990)
- Shihui Zhang (ORCID: https://orcid.org/0000-0002-6418-5513)
- Xing Cheng (ORCID: https://orcid.org/0000-0002-4059-1939)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- National Cancer Center (US)
Publication Details
- Journal
- World Journal of Surgical Oncology
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1186/s12957-025-03818-x
- Citations
- 3
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- Peking Union Medical College
- Cancer Foundation of China
- Bijzonder Onderzoeksfonds UGent